1 Like
Kan noen forklare?
4 Likes
Pledging of shares is an arrangement in which the promoters of a company use their shares as collateral to fulfil their financial requirements. Pledging of shares is common for companies that have high shares owned by investors. The borrower of pledged shares retains ownership of the assets and continues to earn interests and capital gains on those shares
Tipper de bruker aksjene som lånegaranti for å delta i en ny emisjon i et av sine andre selskaper. (Oncoinvent comes to mind)
3 Likes
Photocure ASA - Annual accounts 2020
Photocure ASA - Notice of the annual general meeting 20 May 2021
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Rodjer (307 likes)
- @Snoeffelen (114 likes)
[quote=“Snoeffelen, post:3801, topic:18877”]
- @Savepig (86 likes)
Resten av topp 10:
-
@togulle (59 likes)
-
@rosk82 (58 likes)
-
@tooeasy891 (45 likes)
-
@CanonBoy (30 likes)
-
@solskimm (29 likes)
-
@myk (19 likes)
-
@Fornybar (18 likes)
Gratulerer!
ABG fornyer BUY på Photocure, kursmål 172
19 Likes
Photocure ASA - Repurchase of restricted shares
Photocure ASA: Invitation to presentation of first quarter 2021 financial results
Photocure ASA: Streaming details for AGM 2021
18-May-2021 08:00:17 - PHOTOCURE ANNOUNCES HEXVIX REGULATORY FILING ACCEPTED FOR REVIEW IN CHILE WITH FAST TRACK DESIGNATION - Reuters News
08:00 Oslo, Norway, May 18, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that notification was given to its partner and exclusive distributor, Genotests SpA by the Instituto de Salud Pública de Chile that the Marketing Authorization Application (MAA) for Hexvix[] has been accepted for regulatory review.
During the regulatory review process, Genotests will begin to prepare for the commercial launch of Hexvix in Chile. In August 2020, Photocure entered into an agreement with Genotests, a privately held company specializing in the marketing of genetic tests for cancer and targeting cancer specialists, to exclusively market and distribute Hexvix in Chile. Under the terms of the agreement, Genotests will fund all costs to secure regulatory approval and commercialize Hexvix in Chile. Photocure will manufacture the product and support Genotests with regulatory activities, training, and promotional materials.
Acceptance of the Hexvix MAA with Fast Track designation by the Chilean regulatory authority is a milestone for both Photocure and Genotests as we move closer to bringing this important solution to bladder cancer patients in the region, said Dan Schneider, President and CEO of Photocure. With Genotests dedication and strong execution on this initiative, we are hopeful that Hexvix will become accessible to patients in Chile in the fourth quarter of this year. This partnership represents Photocures first step into the South American continent, and supports our strategy of expanding the availability of Hexvix into new territories to ensure that patients and urologists have access to the benefits of using blue light cystoscopy (BLC[]). The procedure with Hexvix, or Cysview, is recommended in consensus treatment guidelines for the management of bladder cancer around the world.
It is a privilege to bring this fantastic product to Chile said Oscar Varas, founder and owner of Genotests. There are approximately 1,500 new bladder cancer cases annually in our country, an estimated 5,000 TURBT* procedures and nearly 11,000 surveillance cystoscopies. We look forward to building on our established network and the successful demonstration of Hexvix Blue Light Cystoscopy, conducted in collaboration with Karl Storz, at the Chilean Urology Conferences in 2018 and 2019, to launch blue light cystoscopy with Hexvix into the Chilean urology community as soon as possible.
*TURBT: trans-urethral resection of bladder tumors
14 Likes
Pent! Snart hele søramerika med hexvix?
2 Likes
Photocure ASA: Results for the first quarter of 2021
4 Likes
Gratulerer til Finansavisen, det ligger ikke til dem å klare selv den enkleste sak;
En dag i fremtiden klarer de kanskje skrive en sak om biotek uten feil, men jeg holder ikke pusten til det skjer.
3 Likes
Likte denne delen 
10 Likes
Photocure ASA: Final grant of conditional share options
1 Like
Photocure ASA - Annual general meeting held
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Rodjer (264 likes)
- @rosk82 (97 likes)
- @Snoeffelen (77 likes)
Resten av topp 10:
-
@Savepig (75 likes)
-
@tooeasy891 (48 likes)
-
@CanonBoy (44 likes)
-
@togulle (40 likes)
-
@OYV (21 likes)
-
@TyrionIV (21 likes)
-
@myk (21 likes)
Gratulerer!
Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors
Er sikkert et godt stykke frem i tid dette, men er BLC + AI/Deep Learning et mulig neste steget for Photocure?
Altså at denne komboen kan gi BLC en enda bedre presisjonsrate?
This small multicenter clinical study clearly shows the potential of AI based classification of BL images allowing for better treatment decisions and potentially higher detection rates.
Conclusion
The results in this study demonstrated the potential of artificial intelligence-based classification models for the diagnostics of bladder cancer based on BL cystoscopic images. In this context, further studies need to be performed in order to build an automatic BL cystoscopic platform that assists physicians in identifying and classifying potential lesions of interest. Applying such platforms into clinical routines aims to assist surgeons and aids the cancer diagnoses. Potentially this technology could increase the detection rates of cancer and improve the relative low specificity of BL imaging. However, the system will not be considered to substitute the opinion of endo-urologists or pathologists for clinical decision making.
7 Likes